Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression

Annals of the New York Academy of Sciences

Volumn 902, Issue , 2000, Pages 27-38

  Henney, Adriano M ^a,c   Ye, Shu ^b   Zhang, Baiping ^b   Jormsjö, Sophia ^a   Whatling, Carl ^b   Eriksson, Per ^a   Hamsten, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONFERENCE PAPER; CONNECTIVE TISSUE; DIET; DISEASE COURSE; ENVIRONMENTAL FACTOR; EXERCISE; EXTRACELLULAR MATRIX; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; SMOKING;

EID: 0034130181     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06298.x     Document Type: Conference Paper

References (24)

1. 1. DAVIES, M.J. 1996. Stability and Instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture. 1995. Circulation 94: 2013-2020.
2. 2. BIRKEDAL-HANSEN, H. et al. 1993. Matrix Metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4: 197-250.
3. 3. DOLLERY, C.M., J. MCEWAN & A.M. HENNEY. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77(5): 863-868.
4. 4. RICHARDSON, P.D., M.J. DAVIES & G.V.R. BORN. 1989. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2:941-944.
5. 5. LENDON, C.L. et al. 1991. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 87: 87-90.
6. 6. HENNEY, A.M. et al. 1991. Stromelysin gene expression in atherosclerotic plaques detected by in situ hybridization. Proc. Natl. Acad. Sci. USA 88: 8154-8158.
7. 7. GALIS, Z.S. et al. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable lesions of human atherosclerotic plaques. J. Clin. Invest. 94: 2493-2503.
8. 8. GALIS, Z.S. et al. 1995. Macrophage foam cells from experimental atheroma constitutively produce matrix degrading proteinases. Proc. Natl. Acad. Sci. USA 92: 402-406.
9. 9. GALIS, Z.S. et al. 1995. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. Methodol. Commun. 9: 974-980.
10. 10. HUMPHRIES, S.E., H. MONTGOMERY, S. YE & A.M. HENNEY. 1997. Genetic tests for coronary artery disease risk: the fibrinogen and stromelysin genes as examples. In Genetics of Common Diseases: Future Therapeutic and Diagnostic Possibilities I.N.M. Day & S.E. Humphries, Eds.: 151-170. Bios Scientific Publishers. Oxford.
11. 11. YE, S. & A.M. HENNEY. 1999. Detection of mutations and DNA polymorphisms in genes involved in cardiovascular disease by polymerase chain reaction and single strand conformation polymorphism analysis. In Molecular Biology of Vascular Disease. A.H. Baker, Ed. Humana Press Inc. Totowa, NJ.
12. 12. QUINONES, S. et al. 1989. Transcriptional regulation of human stromelysin. J. Biol. Chem. 264: 8339-8344.
13. 13. YE, S.et al. 1995. Variation in the human stromelysin gene promoter is associated with progression of atherosclerosis. Brit. Heart J. 73: 209-215.
14. 14. YE, S. et al. 1996. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression J. Biol. Chem. 271(22): 13055-13060.
15. 15. DE MAAT, M.P.M. et al. 1999. Risk of progression of coronary atherosclerosis is influenced by a common functional variant in the human stromelysin-1 gene promoter. Am. J. Cardiol. 83: 852-856.
16. 16. YE, S., C. WHATLING & A.M. HENNEY. 1999. Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. FEBS Lett. 450: 268-272.
17. 17. HUHTALA, P. et al. 1991. Complete structure of the human gene for 92-kDa type IV collagenase: divergent regulation of expression for the 92-and 72 kilodalton enzyme genes in HT-1080 cells. J. Biol. Chem. 266: 16485-16490.
18. 18. ST. JEAN, P.L. et al. 1995. Characterization of a dinucleotide repeat in the 92kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Ann. Hum. Genet. 59: 17-24.
19. 19. ZHANG, B.P. et al. 1999. Functional polymorphism in the regulatory region of the gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99: 1788-1794.
20. 20. BROWN, D. et al. 1995. Identification of 92kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 91: 2125-2131.
21. 21. VAN DER WAL, A.C. et al. 1994. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterised by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89: 36-44.
22. 22. DAVIES, M.J. et al. 1989. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischemic death. Eur. Heart J. 10: 203-208.
23. 23. TERASHIMA, M. et al. 1999. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 99: 2717-2719.
24. 24. CARMELIET, P. et al. 1997. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genetics 17: 439-444.